EzeRx partners Himachal Pradesh govt to envision an anemia mukt bharat

New Delhi: EzeRx, a leading MedTech company, has joined hands with the Himachal Pradesh Government to tackle the anemia crisis.

EzeRx showcased its flagship product, ‘EzeCheck,’ the world’s first ICMR-validated non-invasive hemoglobin screening device, at a health camp held on January 15th at Civil Hospital, Solan, Himachal Pradesh.

EzeCheck was deployed in the state during 2022-23 after rigorous validation, these life-saving devices are now being introduced across Himachal Pradesh to effectively combat anemia.

The unveiling of the device took place in the presence of Sanjay Awasthi, Chief Parliamentary Secretary, Government of Himachal Pradesh. EzeRx also initiated mass screening at the camp at Arki, testing over 750+ individuals on the first day—a substantial step towards the collective goal of making Himachal Pradesh anemia-free.

Partha Pratim Das Mahapatra, Founder and CEO of, EzeRx said, “EzeCheck, the world’s first non-invasive hemoglobin screening device, has already made strides in 17+ states. With 23 lakh+ screening, we are poised to make a significant impact in Himachal Pradesh. In this challenging hilly terrain where transportation is difficult, residents face numerous obstacles in getting blood tests. Embarking on this journey with the Himachal Pradesh Government is a testament to EzeRx’s commitment to revolutionizing healthcare.”

Das added: “At EzeRx, we believe that healthcare should be both accessible and proactive. EzeCheck our flagship product goes beyond being just a device—it embodies our dedication to innovation, precision, and a healthier future for all. We along with the Himachal Pradesh government envision an anemia-free Himachal Pradesh and further an anemia-free India. EzeCheck, an AI-enabled non-invasive device, aligns seamlessly with this mission.”

Anemia is a prevalent health challenge in India, especially among women aged 15-49. It has an alarming overall prevalence of 57.6%, focusing on vulnerable groups such as adolescent girls, pregnant women, and children under 5 years of age.